| Title |
Low Dose of Doxorubicin Potentiates the Effect of Temozolomide in Glioblastoma Cells
|
|---|---|
| Published in |
Molecular Neurobiology, June 2017
|
| DOI | 10.1007/s12035-017-0611-6 |
| Pubmed ID | |
| Authors |
Emilly Schlee Villodre, Franciele Cristina Kipper, Andrew Oliveira Silva, Guido Lenz, Patrícia Luciana da Costa Lopez |
| Abstract |
Glioblastoma (GBM) is an aggressive brain tumor with temozolomide (TMZ)-based chemotherapy as the main therapeutic strategy. Doxorubicin (DOX) is not used in gliomas due to its low bioavailability in the brain; however, new delivery strategies and low doses may be effective in the long term, especially as part of a drug cocktail. Our aim was to evaluate the chronic effects of low doses of DOX and TMZ in GBM. Human U87-ATCC cells and a primary GBM culture were chronically treated with TMZ (5 μM) and DOX (1 and 10 nM) alone or combined. DOX resulted in a reduction in the number of cells over a period of 35 days and delayed the cell regrowth. In addition, DOX induced cell senescence and reduced tumor sphere formation and the proportion of NANOG- and OCT4-positive cells after 7 days. Low doses of TMZ potentiated the effects of DOX on senescence and sphere formation. This combined response using low doses of DOX may pave the way for its use in glioma therapy, with new technologies to overcome its low blood-brain barrier permeability. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 50% |
| Portugal | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 46 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 14 | 30% |
| Researcher | 6 | 13% |
| Student > Bachelor | 5 | 11% |
| Student > Master | 5 | 11% |
| Student > Doctoral Student | 4 | 9% |
| Other | 5 | 11% |
| Unknown | 7 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 10 | 22% |
| Agricultural and Biological Sciences | 6 | 13% |
| Chemistry | 6 | 13% |
| Medicine and Dentistry | 6 | 13% |
| Neuroscience | 2 | 4% |
| Other | 4 | 9% |
| Unknown | 12 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 June 2017.
All research outputs
#17,899,796
of 22,981,247 outputs
Outputs from Molecular Neurobiology
#2,349
of 3,481 outputs
Outputs of similar age
#227,100
of 317,529 outputs
Outputs of similar age from Molecular Neurobiology
#71
of 117 outputs
Altmetric has tracked 22,981,247 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,481 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,529 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 117 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.